Analysts Set Expectations for Pyxis Oncology Q1 Earnings

Pyxis Oncology, Inc. (NASDAQ:PYXS) – Research analysts at William Blair issued their Q1 2025 earnings per share estimates for Pyxis Oncology in a report issued on Tuesday, March 18th. William Blair analyst A. Hsieh anticipates that the company will post earnings per share of ($0.32) for the quarter. The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.04) per share. William Blair also issued estimates for Pyxis Oncology’s Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.31) EPS, FY2025 earnings at ($1.26) EPS and FY2026 earnings at ($1.32) EPS.

Pyxis Oncology (NASDAQ:PYXS) last announced its earnings results on Tuesday, March 18th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.01. The firm had revenue of $16.15 million for the quarter.

A number of other equities analysts have also weighed in on PYXS. Royal Bank of Canada reiterated an “outperform” rating and issued a $8.00 price target on shares of Pyxis Oncology in a research report on Wednesday. HC Wainwright reiterated a “buy” rating and issued a $5.00 price target on shares of Pyxis Oncology in a research report on Wednesday. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, Pyxis Oncology currently has a consensus rating of “Moderate Buy” and an average target price of $9.20.

Pyxis Oncology Stock Up 8.0 %

NASDAQ:PYXS opened at $1.21 on Friday. Pyxis Oncology has a 1-year low of $0.99 and a 1-year high of $6.18. The firm has a market capitalization of $74.52 million, a price-to-earnings ratio of -1.17 and a beta of 1.11. The stock has a fifty day simple moving average of $1.33 and a 200 day simple moving average of $2.36.

Institutional Investors Weigh In On Pyxis Oncology

Several hedge funds have recently bought and sold shares of PYXS. LMR Partners LLP purchased a new stake in Pyxis Oncology in the 3rd quarter worth about $294,000. Intech Investment Management LLC purchased a new stake in shares of Pyxis Oncology during the 3rd quarter worth about $55,000. MetLife Investment Management LLC raised its stake in shares of Pyxis Oncology by 41.1% during the 3rd quarter. MetLife Investment Management LLC now owns 18,818 shares of the company’s stock worth $69,000 after purchasing an additional 5,484 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Pyxis Oncology during the 3rd quarter worth about $1,405,000. Finally, State Street Corp raised its stake in shares of Pyxis Oncology by 28.0% during the 3rd quarter. State Street Corp now owns 951,251 shares of the company’s stock worth $3,491,000 after purchasing an additional 208,344 shares in the last quarter. 39.09% of the stock is owned by hedge funds and other institutional investors.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.